Opinions+
Perspectives on issues affecting biopharma and health care.
Most Read
What’s next for diagnostic labs, a ‘bright spot’ during Covid-19?
More pharma companies should make the move toward becoming environmentally sustainable
The FDA should embrace remote and automated drug inspection technology
Developers of microbiome-based drugs face challenges. There are ways to overcome them
Rethinking triage in an era of vaccine nationalism
Create a U.S. Institute of Health Technology Assessment to preserve innovation and control costs
Building the perfect wearable for clinical trials
All Coverage
advertisement
